YADANZIOSIDE I


Synonyms	Yadanzioside I
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	QVXFIBXCQCYPLP-WQZWDNGFSA-N
Smiles	COC(=O)[C@]12OC[C@@]34[C@@H](C[C@H]5C(=C(O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(=O)C[C@]5(C)[C@H]3[C@@H](O)[C@@H]1O)C)OC(=O)[C@H](OC(=O)C)[C@@H]24
InChI	InChI=1S/C29H38O16/c1-9-11-5-14-28-8-41-29(26(39)40-4,22(28)20(24(38)44-14)42-10(2)31)23(37)18(36)21(28)27(11,3)6-12(32)19(9)45-25-17(35)16(34)15(33)13(7-30)43-25/h11,13-18,20-23,25,30,33-37H,5-8H2,1-4H3/t11-,13+,14+,15+,16-,17+,18+,20+,21+,22+,23-,25-,27-,28+,29+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C29H38O16
Molecular Weight	642.6
AlogP	-3.3
Hydrogen Bond Acceptor	16.0
Hydrogen Bond Donor	6.0
Number of Rotational Bond	7.0
Polar Surface Area	245.03
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	45.0

Assay Description	Organism	Bioactivity
Antiviral activity against Tobacco mosaic virus strain U1 (TMV) infected Nicotiana tabacum cv. K326 leaves assessed as decrease in Tobacco mosaic virus coat protein level at 20 uM at 25 degC treated at 6 hr after viral inoculation measured after 48 hr by leaf disk method/western blot analysis	Tobacco mosaic virus	None
In vivo antiviral activity against Tobacco mosaic virus strain U1 (TMV) infected left side of Nicotiana glutinosa leaves assessed as decrease in local lesion numbers co-incubated with virus for 30 min before inoculation onto leaves measured at 3-4 days after viral challenge by half-leaf method	Tobacco mosaic virus	4220.0 nM
In vivo antiviral activity against Tobacco mosaic virus strain U1 (TMV) infected left side of Nicotiana glutinosa leaves assessed as decrease in local lesion numbers at 10 uM co-incubated with virus for 30 min before inoculation onto leaves measured at 3-4 days after viral challenge by half-leaf method	Tobacco mosaic virus	67.9 %
In vivo antiviral activity against Tobacco mosaic virus strain U1 (TMV) infected left side of Nicotiana glutinosa leaves assessed as decrease in local lesion numbers at 5 uM co-incubated with virus for 30 min before inoculation onto leaves measured at 3-4 days after viral challenge by half-leaf method	Tobacco mosaic virus	54.9 %
In vivo antiviral activity against Tobacco mosaic virus strain U1 (TMV) infected left side of Nicotiana glutinosa leaves assessed as decrease in local lesion numbers at 2.5 uM co-incubated with virus for 30 min before inoculation onto leaves measured at 3-4 days after viral challenge by half-leaf method	Tobacco mosaic virus	35.4 %
In vivo antiviral activity against Tobacco mosaic virus strain U1 (TMV) infected left side of Nicotiana glutinosa leaves assessed as decrease in local lesion numbers at 1.25 uM co-incubated with virus for 30 min before inoculation onto leaves measured at 3-4 days after viral challenge by half-leaf method	Tobacco mosaic virus	26.1 %
In vivo antiviral activity against Tobacco mosaic virus strain U1 (TMV) infected left side of Nicotiana glutinosa leaves assessed as decrease in local lesion numbers at 20 uM co-incubated with virus for 30 min before inoculation onto leaves measured at 3-4 days after viral challenge by half-leaf method	Tobacco mosaic virus	81.5 %

Cross References

Resources	Reference
ChEMBL	CHEMBL506706
PubChem	10484290

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).